# Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

> **NCT00416650** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00416650
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2007-10
- **Final completion:** 2013-03
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2013-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00416650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00416650, "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00416650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*